1769 related articles for article (PubMed ID: 8324014)
1. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins.
Gillies SD; Young D; Lo KM; Roberts S
Bioconjug Chem; 1993; 4(3):230-5. PubMed ID: 8324014
[TBL] [Abstract][Full Text] [Related]
2. Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities.
Dreier T; Lode HN; Xiang R; Dolman CS; Reisfeld RA; Kang AS
Bioconjug Chem; 1998; 9(4):482-9. PubMed ID: 9667950
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
Schanzer JM; Fichtner I; Baeuerle PA; Kufer P
J Immunother; 2006; 29(5):477-88. PubMed ID: 16971804
[TBL] [Abstract][Full Text] [Related]
4. Deficient antigen presentation by Langerhans cells from athymic (nu/nu) mice. Restoration with thymic transplantation or administration of cytokines.
Grabbe S; Gallo RL; Lindgren A; Granstein RD
J Immunol; 1993 Oct; 151(7):3430-9. PubMed ID: 8376784
[TBL] [Abstract][Full Text] [Related]
5. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
6. Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties.
Hornick JL; Khawli LA; Hu P; Lynch M; Anderson PM; Epstein AL
Blood; 1997 Jun; 89(12):4437-47. PubMed ID: 9192768
[TBL] [Abstract][Full Text] [Related]
7. Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-alpha show improved pharmacokinetics and biological activity and reduced toxicity in mice.
Kedar E; Palgi O; Golod G; Babai I; Barenholz Y
J Immunother; 1997 May; 20(3):180-93. PubMed ID: 9181456
[TBL] [Abstract][Full Text] [Related]
8. Fusion cytokine IL-2-GMCSF enhances anticancer immune responses through promoting cell-cell interactions.
Wen Q; Xiong W; He J; Zhang S; Du X; Liu S; Wang J; Zhou M; Ma L
J Transl Med; 2016 Feb; 14():41. PubMed ID: 26850448
[TBL] [Abstract][Full Text] [Related]
9. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL
Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368
[TBL] [Abstract][Full Text] [Related]
10. Antitumor efficacy induced by human ovarian cancer cells secreting IL-21 alone or combination with GM-CSF cytokines in nude mice model.
Dou J; Wang Y; Wang J; Zhao F; Li Y; Cao M; Hu W; Hu K; He XF; Chu L; Jiang C; Gu N
Immunobiology; 2009; 214(6):483-92. PubMed ID: 19389515
[TBL] [Abstract][Full Text] [Related]
11. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity.
Dela Cruz JS; Trinh KR; Morrison SL; Penichet ML
J Immunol; 2000 Nov; 165(9):5112-21. PubMed ID: 11046042
[TBL] [Abstract][Full Text] [Related]
12. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
13. Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer.
Gillies SD; Lan Y; Brunkhorst B; Wong WK; Li Y; Lo KM
Cancer Immunol Immunother; 2002 Oct; 51(8):449-60. PubMed ID: 12202906
[TBL] [Abstract][Full Text] [Related]
14. A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells.
Schanzer JM; Baeuerle PA; Dreier T; Kufer P
Cancer Immun; 2006 Feb; 6():4. PubMed ID: 16483188
[TBL] [Abstract][Full Text] [Related]
15. Construction and characterization of a chimeric fusion protein consisting of an anti-idiotype antibody mimicking a breast cancer-associated antigen and the cytokine GM-CSF.
Tripathi PK; Qin H; Bhattacharya-Chatterjee M; Ceriani RL; Foon KA; Chatterjee SK
Hybridoma; 1999 Apr; 18(2):193-202. PubMed ID: 10380019
[TBL] [Abstract][Full Text] [Related]
16. Regulation of granulocyte macrophage colony stimulating factor production by human articular chondrocytes. Induction by both tumor necrosis factor-alpha and interleukin 1, downregulation by transforming growth factor beta and upregulation by fibroblast growth factor.
Alsalameh S; Firestein GS; Oez S; Kurrle R; Kalden JR; Burmester GR
J Rheumatol; 1994 Jun; 21(6):993-1002. PubMed ID: 7932447
[TBL] [Abstract][Full Text] [Related]
17. The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells.
Ozbek S; Peters M; Breuhahn K; Mann A; Blessing M; Fischer M; Schirmacher P; Mackiewicz A; Rose-John S
Oncogene; 2001 Feb; 20(8):972-9. PubMed ID: 11314032
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
19. IL-4 and TNF-alpha-mediated proliferation of the human megakaryocytic line M-O7E is regulated by induced autocrine production of GM-CSF.
Wadhwa M; Dilger P; Meager A; Walker B; Gaines-Das R; Thorpe R
Cytokine; 1996 Dec; 8(12):900-9. PubMed ID: 9050748
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice.
Kendra K; Gan J; Ricci M; Surfus J; Shaker A; Super M; Frost JD; Rakhmilevich A; Hank JA; Gillies SD; Sondel PM
Cancer Immunol Immunother; 1999 Aug; 48(5):219-29. PubMed ID: 10478638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
